Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03962725 · ClinicalTrials.gov registry record · Phase 4
Avoiding Neuromuscular Blockers to Reduce Complications
A Phase 4 study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT03962725 is a Phase 4 study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 3 participants.
The verdict
NCT03962725, a Phase 4 study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
The goal of this study to evaluate whether eliminating the use of non-depolarizing neuromuscular blocking agents (NMBA) for maintenance of general anesthesia reduces postoperative pulmonary complications in higher risk patients.
Interventions
- DRUG Neuromuscular Blocking Agents
- DRUG Anesthetic Adjuncts
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-08-07 |
| Est. Completion | 2022-12-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03962725
The ClinicalTrials.gov registry entry for NCT03962725 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Neuromuscular Blocking Agents is the first listed.
NCT03962725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03962725 about?
NCT03962725 is a clinical study titled "Avoiding Neuromuscular Blockers to Reduce Complications". The goal of this study to evaluate whether eliminating the use of non-depolarizing neuromuscular blocking agents (NMBA) for maintenance of general anesthesia reduces postoperative pulmonary complications in higher risk patients.
What is the current status of trial NCT03962725?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2019-08-07. Estimated completion is 2022-12-19.
What interventions are being tested in trial NCT03962725?
The interventions under investigation include: Neuromuscular Blocking Agents (DRUG), Anesthetic Adjuncts (DRUG).
Who is sponsoring clinical trial NCT03962725?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.